Maternal Serum Osteopontin Levels in Pregnant Women Diagnosed With PPROM

NCT07626385 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 71

Last updated 2026-06-04

No results posted yet for this study

Summary

Preterm prelabor rupture of membranes (PPROM) is defined as the rupture of the fetal membranes prior to the onset of labor and before 37 weeks of gestation; it occurs in approximately 2-3% of all pregnancies and accounts for a significant proportion of preterm births .

Current data indicate that PPROM is not merely a clinical condition limited to membrane rupture; rather, it is a biological process associated with loss of structural integrity in the fetal membranes, an inflammatory-oxidative stress response, and cellular aging . The fetal membranes constitute a dynamic barrier that provides mechanical and immunological protection for the fetus throughout pregnancy .

There is limited data in the literature investigating the relationship between osteopontin and preterm birth. In particular, it has been reported that osteopontin levels may be higher in amniotic fluid samples collected during the second trimester from pregnant women who subsequently experienced spontaneous preterm birth . However, the changes in maternal serum osteopontin levels in cases of PPROM and the clinical significance of these changes remain unclear. Therefore, osteopontin levels may vary across different biological compartments and at different stages of pregnancy. To address this knowledge gap, the present study aimed to compare maternal serum osteopontin levels between pregnant women diagnosed with PPROM and those with term membrane rupture.

Conditions

  • Preterm Labor

Interventions

DIAGNOSTIC_TEST

SERUM OSTEOPONTİN

At the time of diagnosis, 5 mL venous blood samples were collected from all participants for biochemical analysis. The samples were centrifuged at 3,000 rpm for 10 minutes to separate the serum, which was then stored at -80°C until analysis. Serum osteopontin levels were measured using a sandwich enzyme-linked immunosorbent assay (ELISA) kit (Human Osteopontin ELISA Kit, Cat. No: E1525Hu, BT Laboratory, China) in accordance with the manufacturer's protocol. This kit has been developed for the quantitative determination of osteopontin levels in serum, plasma, and other biological fluids. The assay principle is based on the pre-coating of microplate wells with an antibody specific to human SPP1. The osteopontin present in the samples was incubated with a biotinylated secondary antibody and a streptavidin-horseradish peroxidase (HRP) complex after binding to this antibody. Following the washing steps, a substrate solution was added, and the resulting color reaction was stopped with an ac

Sponsors & Collaborators

  • Batman University

    collaborator OTHER
  • Batman Training and Research Hospital

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-09
Primary Completion
2026-05-12
Completion
2026-05-12

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07626385 on ClinicalTrials.gov